Please use this identifier to cite or link to this item:
http://doi.org/10.25358/openscience-9017Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Haist, Maximilian | - |
| dc.contributor.author | Stege, Henner | - |
| dc.contributor.author | Kuske, Michael | - |
| dc.contributor.author | Bauer, Julia | - |
| dc.contributor.author | Klumpp, Annika | - |
| dc.contributor.author | Grabbe, Stephan | - |
| dc.contributor.author | Bros, Matthias | - |
| dc.date.accessioned | 2023-04-21T09:36:12Z | - |
| dc.date.available | 2023-04-21T09:36:12Z | - |
| dc.date.issued | 2023 | - |
| dc.identifier.uri | https://openscience.ub.uni-mainz.de/handle/20.500.12030/9034 | - |
| dc.description.abstract | The approval of immune-checkpoint inhibitors (CPI) and mitogen activated protein kinase inhibitors (MAPKi) in recent years significantly improved the treatment management and survival of patients with advanced malignant melanoma. CPI aim to counter-act receptor-mediated inhibitory effects of tumor cells and immunomodulatory cell types on effector T cells, whereas MAPKi are intended to inhibit tumor cell survival. In agreement with these complementary modes of action preclinical data indicated that the combined application of CPI and MAPKi or their optimal sequencing might provide additional clinical benefit. In this review the rationale and preclinical evidence that support the combined application of MAPKi and CPI either in concurrent or consecutive regimens are presented. Further, we will discuss the results from clinical trials investigating the sequential or combined application of MAPKi and CPI for advanced melanoma patients and their implications for clinical practice. Finally, we outline mechanisms of MAPKi and CPI cross-resistance which limit the efficacy of currently available treatments, as well as combination regimens. | en_GB |
| dc.description.sponsorship | Deutsche Forschungsgemeinschaft (DFG)|491381577|Open-Access-Publikationskosten 2022–2024 Universität Mainz - Universitätsmedizin | - |
| dc.language.iso | eng | de |
| dc.rights | CC BY | * |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | * |
| dc.subject.ddc | 610 Medizin | de_DE |
| dc.subject.ddc | 610 Medical sciences | en_GB |
| dc.title | Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy : the more, the better? | en_GB |
| dc.type | Zeitschriftenaufsatz | de |
| dc.identifier.doi | http://doi.org/10.25358/openscience-9017 | - |
| jgu.type.dinitype | article | en_GB |
| jgu.type.version | Published version | de |
| jgu.type.resource | Text | de |
| jgu.organisation.department | FB 04 Medizin | de |
| jgu.organisation.number | 2700 | - |
| jgu.organisation.name | Johannes Gutenberg-Universität Mainz | - |
| jgu.rights.accessrights | openAccess | - |
| jgu.journal.title | Cancer and metastasis reviews | de |
| jgu.journal.volume | Version of Record (VoR) | de |
| jgu.publisher.year | 2023 | - |
| jgu.publisher.name | Springer Science + Business Media B.V. | de |
| jgu.publisher.place | Dordrecht u.a. | de |
| jgu.publisher.issn | 1573-7233 | de |
| jgu.organisation.place | Mainz | - |
| jgu.subject.ddccode | 610 | de |
| jgu.publisher.doi | 10.1007/s10555-023-10097-z | de |
| jgu.organisation.ror | https://ror.org/023b0x485 | - |
| Appears in collections: | DFG-491381577-H | |
Files in This Item:
| File | Description | Size | Format | ||
|---|---|---|---|---|---|
 | combination_of_immunecheckpoi-20230417154826296.pdf | 3.8 MB | Adobe PDF | View/Open |